CSL - Operating Profit


CSL reported $2.64B in Operating Profit for its fiscal semester ending in December of 2025.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Arca Biopharma USD -36.43M 2M Mar/2026
aTyr Pharma USD -128K 24.6M Mar/2026
Bio Path USD -297K 191K Mar/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
CSL USD 2.64B 1.97B Dec/2025
Curis USD -11.52M 3.64M Mar/2026
Immunic USD -23.33M 2.67M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
TherapeuticsMD USD -1.18M 40K Jun/2024